IMUX

Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist

Immunic Stock Jumps As FDA Signs Off On 2 Clinical Trial Applications

IMUX Stock Price Increases Over 5% Pre-Market: Why It Happened

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in July

Immunic, Inc. to Participate in Industry and Investor Conferences in June